YS Biopharma Co, Valuation
| YSDelisted Stock | 0.48 0.03 5.88% |
YS Biopharma is overvalued. YS Biopharma Co, owns a latest Real Value of USD0.46 per share. The recent price of the company is USD0.48. Our model calculates the value of YS Biopharma Co, from evaluating the company fundamentals such as number of shares shorted of 38.89 K, and Return On Asset of -0.1 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that YS Biopharma's price fluctuation is very steady at this time. Calculation of the real value of YS Biopharma Co, is based on 3 months time horizon. Increasing YS Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the YS Biopharma stock is determined by what a typical buyer is willing to pay for full or partial control of YS Biopharma Co,. Since YS Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of YS Biopharma Stock. However, YS Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.48 | Real 0.46 | Hype 0.48 | Naive 0.5 |
The intrinsic value of YS Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence YS Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of YS Biopharma Co, helps investors to forecast how YS Biopharma stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of YS Biopharma more accurately as focusing exclusively on YS Biopharma's fundamentals will not take into account other important factors: YS Biopharma Total Value Analysis
YS Biopharma Co, is at this time projected to have takeover value of 429.47 M with market capitalization of 192.09 M, debt of 498.63 M, and cash on hands of . Please note that takeover value may be misleading and is a subject to accounting mistakes. We encourage investors to methodically examine all of the YS Biopharma fundamentals before making investment evaluation based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
429.47 M | 192.09 M | 498.63 M |
YS Biopharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. YS Biopharma has an asset utilization ratio of 39.96 percent. This implies that the Company is making USD0.4 for each dollar of assets. An increasing asset utilization means that YS Biopharma Co, is more efficient with each dollar of assets it utilizes for everyday operations.YS Biopharma Ownership Allocation
YS Biopharma Co, secures a total of 188.33 Million outstanding shares. YS Biopharma Co, owns majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 81.42 % of YS Biopharma Co, outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company retains, if the real value of the company is less than the current market value, you may not be able to make money on it.YS Biopharma Profitability Analysis
The company generated the yearly revenue of 687.2 M. Annual Net Loss to common stockholders was (145.48 M) with gross profit of 0.About YS Biopharma Valuation
The delisted stock valuation mechanism determines YS Biopharma's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of YS Biopharma Co, based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of YS Biopharma. We calculate exposure to YS Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of YS Biopharma's related companies.YS Biopharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as YS Biopharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 93.1 M | |
| Quarterly Earnings Growth Y O Y | 9.461 |
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in YS Biopharma Stock
If you are still planning to invest in YS Biopharma Co, check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the YS Biopharma's history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |